Kyowa Kirin Co Ltd - Company Profile
Powered by 
All the sales intelligence you need on Kyowa Kirin Co Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Kyowa Kirin Co Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Kyowa Kirin Co Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Kyowa Kirin Co Ltd (Kyowa Kirin), a subsidiary of Kirin Holdings Co Ltd, is an R&D-based life sciences company. It primarily engages in the discovery, development, manufacturing, commercialization, and marketing of pharmaceuticals and biotechnology products. The company’s major products include innovative drugs in the therapeutic areas of oncology, nephrology, central nervous system, and immunology. Its development pipeline consists of various protein, antibody, and small and large molecule formulations for the treatment of hypophosphatemia, achondroplasia, acute myeloid leukaemia, Hurler syndrome, solid tumors, and cutaneous lupus erythematosus, among others. The company operates through a network of subsidiaries in the US, Europe, and Asia. It offers its products to customers through brands Crysvita, Poteligeo, and Nourianz/Nouriast. Kyowa Kirin is headquartered in Tokyo, Japan.
Headquarters
Japan
Address
Otemachi Financial City Grand Cube, 1-9-2, Ote-Machi, Chiyoda-Ku, Tokyo, 100-0004
Website
www.kyowakirin.co.jp
Telephone
81 352 057200
No of Employees
5,161
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
4151 (TYO)
Revenue (2024)
$3.2B
12.1%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-26.3%
(2024 vs 2023)
Market Cap*
$7.9B
Net Profit Margin (2023)
XYZ
-34.2%
(2024 vs 2023)
* As of and is in US$
Kyowa Kirin Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Recombinant Fully Human Monoclonal Ig G1 Antibody | Pasetocin |
| Humanized Monoclonal Antibody | Adriacin |
| Adenosine A2a Receptor Antagonist | Fortimicin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In November, the company and Kura Oncology secured full approval of KOMZIFTI (ziftomenib) for adult patients with relapsed or refractory (R/R) acute myeloid leukemia. |
| 2025 | New Products/Services | In November, the company announced the launch of Lumicef subcutaneous injection 210 mg pen in Japan. |
| 2025 | New Products/Services | In November, the company announced the launch of Crysvita prefilled syringe formulation in Japan. |
Competitor Comparison
| Key Parameters | Kyowa Kirin Co Ltd | Takeda Pharmaceutical Co Ltd | Chugai Pharmaceutical Co Ltd | Eisai Co Ltd | Taisho Pharmaceutical Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Japan | Japan | Japan | Japan | Japan |
| City | Chiyoda-Ku | Chuo-Ku | Chuo-Ku | Bunkyo-Ku | Toshima |
| State/Province | Tokyo | Tokyo | Tokyo | Tokyo | Tokyo |
| No. of Employees | 5,161 | 47,455 | 7,872 | 13,506 | 8,784 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Masashi Miyamoto, PhD | Chairman | Executive Board | 2025 | 67 |
| Abdul Mullick, PhD | President; Chief Executive Officer; Director | Executive Board | 2026 | 59 |
| Takeyoshi Yamashita, PhD | Chief Scientific Officer; Director; Executive Vice President | Executive Board | 2026 | - |
| Koji Igarashi | Chief Financial Officer | Senior Management | 2026 | - |
| Colin Sims | Chief Strategy Officer | Senior Management | 2026 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer